Standard Review for MRK Fertility Drug - Analyst Blog

By
A A A

Merck ( MRK ) recently announced that the FDA has granted standard review for its new drug application (NDA) for fertility candidate, corifollitropin alfa. Merck is looking to get the candidate approved for controlled ovarian stimulation (COS) in women participating in assisted reproductive technology.

FDA approval would make corifollitropin alfa the first sustained follicular stimulant to be approved for use in a fertility treatment regimen.

We note that the candidate is already approved in more than 50 markets outside the U.S. including the EU where it is known as Elonva.

Merck, which is facing generic competition for erstwhile blockbuster drug, Singulair, is working on developing its pipeline to help make up for the loss of revenues resulting from genericization. The company currently has several candidates under regulatory review including its ragweed pollen (ambrosia artemisiifolia) sublingual allergy immunotherapy tablet, sugammadex and vorapaxar.

While Merck is looking to get sugammadex approved for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium, vorapaxar is under FDA review for the secondary prevention of cardiovascular events in patients with a history of heart attack and no history of stroke or transient ischemic attack (TIA).

Merck currently carries a Zacks Rank #3 (Hold). The company has been facing headwinds in the form of Singulair's loss of exclusivity, unfavorable currency movement and pipeline setbacks. We believe Merck will look towards cost-cutting initiatives and share buybacks to drive the bottom-line.

At present, companies like Questcor Pharmaceuticals, Inc. ( QCOR ), Forest Laboratories Inc. ( FRX ) and Jazz Pharmaceuticals ( JAZZ ) look well-positioned. While Questcor is a Zacks Rank #1 (Strong Buy) stock, Forest Labs and Jazz are Zacks Rank #2 (Buy) stocks.



FOREST LABS A (FRX): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

QUESTCOR PHARMA (QCOR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: COS , FRX , JAZZ , MRK , NMB

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Your Car Is Spying on You
Your Car Is Spying on You           

Stocks

Referenced

86%
100%

Most Active by Volume

73,078,214
  • $30.33 ▼ 3.90%
57,046,796
  • $15.52 ▲ 0.45%
51,290,831
  • $100.57 ▲ 0.04%
39,855,468
  • $8.13 ▲ 1.37%
31,693,544
  • $5.50 ▲ 20.35%
31,532,510
  • $10.33 ▲ 0.78%
31,526,753
  • $39.10 ▲ 47.21%
28,366,542
  • $26.36 ▲ 1.19%
As of 8/20/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com